{
  "title": "Teva CEO on Staying Competitive in Generic Drug Market",
  "itunes:title": "Teva CEO on Staying Competitive in Generic Drug Market",
  "description": "<p>Kåre Schultz, CEO at Teva Pharmaceutical, talks about the company's restructuring plans as well as his outlook for drug development. He says more than 90% of U.S. pharmaceuticals are generics and one out of ten drugs is produced by Teva.</p><p>Host: Jason Kelly. Producer: Doni Holloway.</p><p>See <a href=\"https://omnystudio.com/listener\">omnystudio.com/listener</a> for privacy information.</p>",
  "content:encoded": "<p>Kåre Schultz, CEO at Teva Pharmaceutical, talks about the company's restructuring plans as well as his outlook for drug development. He says more than 90% of U.S. pharmaceuticals are generics and one out of ten drugs is produced by Teva.</p><p>Host: Jason Kelly. Producer: Doni Holloway.</p><p>See <a href=\"https://omnystudio.com/listener\">omnystudio.com/listener</a> for privacy information.</p>",
  "itunes:episodeType": "full",
  "itunes:author": "Bloomberg",
  "itunes:image": "",
  "media:content": [
    {
      "media:player": ""
    },
    ""
  ],
  "guid": "2847e588-4e83-11ea-85cf-23c049faa5f7",
  "omny:clipId": "72f2e7d6-b702-4b80-85e2-ae2b00830daf",
  "pubDate": "Thu, 13 Feb 2020 17:07:47 +0000",
  "itunes:duration": 846,
  "enclosure": "",
  "link": "https://omny.fm/shows/bloomberg-businessweek/teva-ceo-on-staying-competitive-in-generic-drug-ma"
}